Literature DB >> 2455016

Identification of human erythrocyte blood group antigens on decay-accelerating factor (DAF) and an erythrocyte phenotype negative for DAF.

M J Telen1, S E Hall, A M Green, J J Moulds, W F Rosse.   

Abstract

Decay accelerating factor (DAF) is a glycoprotein present on the surfaces of many types ofcells in contact with plasma, including erythrocytes, leukocytes, and platelets (reviewed in reference 1). A small amount of DAF is also present in serum. Numerous investigators have demonstrated that DAF inhibits the action of C3 convertases on cell surfaces, and its absence has been shown to be at least partially responsible for the abnormal sensitivity to lysis by complement exhibited by erythrocytes of patients with the acquired stem cell disorder paroxysmal nocturnal hemoglobinuria (PNH) (2). Hereditary absence of DAF has not been previously described. Tc(a) and Cr(a) are high-frequency human erythrocyte antigens . These antigens are part of a family of blood group antigens, designated Cromer related, which are all absent from the null phenotype cell IFC(-) , or Inab (3). Recently, Spring and colleagues (4) have identified two monoclonal antibodies which bound to high frequency red cell antigens absent from the Inab phenotype. They also demonstrated that these antibodies, as well as several human antisera to Cromer-related antigens, bound to a 70-kD glycoprotein when used to stain immunoblots of human erythrocyte membrane proteins . Because the wide tissue distribution of mAb reactivity, along with some of the biochemical characterization and immunoblotting data, was similar to that of DAF, we investigated whether the Cromer-related antigens Cr(a) and Tc(a) resided on the DAF molecule.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2455016      PMCID: PMC2189670          DOI: 10.1084/jem.167.6.1993

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  14 in total

1.  The control of complement activation by the blood cells in paroxysmal nocturnal hemoglobinuria.

Authors:  W F Rosse
Journal:  Blood       Date:  1986-02       Impact factor: 22.113

2.  Biosynthesis and glycosylation of the human complement regulatory protein decay-accelerating factor.

Authors:  D M Lublin; J Krsek-Staples; M K Pangburn; J P Atkinson
Journal:  J Immunol       Date:  1986-09-01       Impact factor: 5.422

3.  Further characterization of erythrocyte p80 and the membrane protein defect of In(Lu) Lu(a-b-) erythrocytes.

Authors:  M J Telen; I Rogers; M Letarte
Journal:  Blood       Date:  1987-11       Impact factor: 22.113

4.  The lysis of paroxysmal nocturnal haemoglobinuria red cells by serum and cobra factor.

Authors:  T Kabakçi; W F Rosse; G L Logue
Journal:  Br J Haematol       Date:  1972-12       Impact factor: 6.998

5.  Separation of the acetylcholinesterase-deficient red cells in paroxysmal nocturnal hemoglobinuria.

Authors:  F L Chow; S E Hall; W F Rosse; M J Telen
Journal:  Blood       Date:  1986-04       Impact factor: 22.113

6.  Isolation of a human erythrocyte membrane glycoprotein with decay-accelerating activity for C3 convertases of the complement system.

Authors:  A Nicholson-Weller; J Burge; D T Fearon; P F Weller; K F Austen
Journal:  J Immunol       Date:  1982-07       Impact factor: 5.422

7.  A possible null phenotype in the Cromer blood group complex.

Authors:  G L Daniels; H Tohyama; M Uchikawa
Journal:  Transfusion       Date:  1982 Sep-Oct       Impact factor: 3.157

8.  Immune lysis of normal human and paroxysmal nocturnal hemoglobinuria (PNH) red blood cells. I. The sensitivity of PNH red cells to lysis by complement and specific antibody.

Authors:  W F Rosse; J V Dacie
Journal:  J Clin Invest       Date:  1966-05       Impact factor: 14.808

9.  Amelioration of lytic abnormalities of paroxysmal nocturnal hemoglobinuria with decay-accelerating factor.

Authors:  M E Medof; T Kinoshita; R Silber; V Nussenzweig
Journal:  Proc Natl Acad Sci U S A       Date:  1985-05       Impact factor: 11.205

10.  Human erythrocyte antigens. Regulation of expression of a novel erythrocyte surface antigen by the inhibitor Lutheran In(Lu) gene.

Authors:  M J Telen; G S Eisenbarth; B F Haynes
Journal:  J Clin Invest       Date:  1983-06       Impact factor: 14.808

View more
  15 in total

1.  Dr(a-) polymorphism of decay accelerating factor. Biochemical, functional, and molecular characterization and production of allele-specific transfectants.

Authors:  D M Lublin; E S Thompson; A M Green; C Levene; M J Telen
Journal:  J Clin Invest       Date:  1991-06       Impact factor: 14.808

2.  Role of decay-accelerating factor in regulating complement activation on the erythrocyte surface as revealed by gene targeting.

Authors:  X Sun; C D Funk; C Deng; A Sahu; J D Lambris; W C Song
Journal:  Proc Natl Acad Sci U S A       Date:  1999-01-19       Impact factor: 11.205

Review 3.  Pathogenesis and mechanisms of antibody-mediated hemolysis.

Authors:  Willy A Flegel
Journal:  Transfusion       Date:  2015-07       Impact factor: 3.157

Review 4.  Complement-mediated haemolysis and the role of blood transfusion in paroxysmal nocturnal haemoglobinuria.

Authors:  Tolulase Olutogun; Ilaria Cutini; Rosario Notaro; Lucio Luzzatto
Journal:  Blood Transfus       Date:  2015-02-02       Impact factor: 3.443

Review 5.  Membrane proteins that protect against complement lysis.

Authors:  B P Morgan; S Meri
Journal:  Springer Semin Immunopathol       Date:  1994

6.  Rapid receptor-clustering assay to detect uropathogenic and diarrheal Escherichia coli isolates bearing adhesins of the Dr family.

Authors:  P Goluszko; R Selvarangan; B J Nowicki; S Nowicki; A Hart; E Pawelczyk; K Nguyen
Journal:  J Clin Microbiol       Date:  2001-06       Impact factor: 5.948

7.  Studies on the defect which causes absence of decay accelerating factor (DAF) from the peripheral blood cells of an individual with the Inab phenotype.

Authors:  C G Tate; M Uchikawa; M J Tanner; P A Judson; S F Parsons; G Mallinson; D J Anstee
Journal:  Biochem J       Date:  1989-07-15       Impact factor: 3.857

Review 8.  Infectious diseases associated with complement deficiencies.

Authors:  J E Figueroa; P Densen
Journal:  Clin Microbiol Rev       Date:  1991-07       Impact factor: 26.132

9.  Decay-accelerating factor ameliorates systemic autoimmune disease in MRL/lpr mice via both complement-dependent and -independent mechanisms.

Authors:  Takashi Miwa; Michael A Maldonado; Lin Zhou; Koei Yamada; Gary S Gilkeson; Robert A Eisenberg; Wen-Chao Song
Journal:  Am J Pathol       Date:  2007-04       Impact factor: 4.307

10.  Rapid cyclic changes in density and accessibility of endometrial ligands for Escherichia coli Dr fimbriae.

Authors:  A K Kaul; D Kumar; M Nagamani; P Goluszko; S Nowicki; B J Nowicki
Journal:  Infect Immun       Date:  1996-02       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.